Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001785530-21-000030
Filing Date
2021-07-02
Accepted
2021-07-02 08:26:19
Documents
1
Period of Report
2021-07-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_162522876528536.html 4  
1 FORM 4 wf-form4_162522876528536.xml 4 4050
  Complete submission text file 0001785530-21-000030.txt   5459
Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Issuer) CIK: 0001785530 (see all company filings)

IRS No.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address
Karunatilake Chulani (Reporting) CIK: 0001867326 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40366 | Film No.: 211068071